Irhythm Technologies Inc (NASDAQ:IRTC) CFO Matthew C. Garrett sold 4,954 shares of Irhythm Technologies stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $80.00, for a total value of $396,320.00. Following the sale, the chief financial officer now owns 21,930 shares of the company’s stock, valued at approximately $1,754,400. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of NASDAQ IRTC traded down $3.30 during mid-day trading on Friday, hitting $86.50. 162,037 shares of the company traded hands, compared to its average volume of 397,690. The business has a 50 day moving average of $77.44 and a two-hundred day moving average of $73.57. The company has a current ratio of 4.07, a quick ratio of 3.99 and a debt-to-equity ratio of 0.86. Irhythm Technologies Inc has a 1 year low of $56.24 and a 1 year high of $98.13.
A number of hedge funds have recently modified their holdings of IRTC. Jennison Associates LLC lifted its position in shares of Irhythm Technologies by 0.8% during the 4th quarter. Jennison Associates LLC now owns 154,781 shares of the company’s stock worth $10,539,000 after buying an additional 1,253 shares during the period. Great Lakes Advisors LLC increased its holdings in Irhythm Technologies by 1.3% during the 4th quarter. Great Lakes Advisors LLC now owns 72,971 shares of the company’s stock valued at $4,969,000 after purchasing an additional 933 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Irhythm Technologies by 5.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 162,793 shares of the company’s stock valued at $11,085,000 after purchasing an additional 7,929 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Irhythm Technologies by 11.9% during the 4th quarter. Victory Capital Management Inc. now owns 488,415 shares of the company’s stock valued at $33,256,000 after purchasing an additional 51,909 shares in the last quarter. Finally, State Street Corp increased its holdings in Irhythm Technologies by 8.4% during the 4th quarter. State Street Corp now owns 674,568 shares of the company’s stock valued at $45,931,000 after purchasing an additional 52,033 shares in the last quarter.
Several analysts have commented on the company. BidaskClub upgraded Irhythm Technologies from a “sell” rating to a “hold” rating in a report on Saturday, January 18th. Oppenheimer assumed coverage on Irhythm Technologies in a report on Tuesday, October 22nd. They issued a “market perform” rating for the company. ValuEngine upgraded Irhythm Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 31st. BTIG Research initiated coverage on Irhythm Technologies in a report on Wednesday. They set a “buy” rating and a $90.00 target price for the company. Finally, Morgan Stanley boosted their price target on Irhythm Technologies from $101.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $101.00.
About Irhythm Technologies
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Recommended Story: What are economic reports?
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.